Johnson & Johnson Unveils Promising New Blood Cancer Therapies at ASH 2025
Reuters
Nov 05
Johnson & Johnson Unveils Promising New Blood Cancer Therapies at ASH 2025
Johnson & Johnson has announced that more than 46 poster presentations and 10 oral presentations on hematologic malignancies and other blood disorders will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The presentations will feature practice-influencing evidence from the company's hematology portfolio and progress on next-generation therapies. Highlights include an oral presentation and seven poster presentations on warm autoimmune hemolytic anemia (wAIHA), focusing on the need for approved therapies for this rare condition. Information on the abstracts is available on the company's website. The results will be presented at the upcoming ASH meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.